Related Experiment Video

Updated: Jul 5, 2026

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Structure-based design of a superagonist ligand for the vitamin D nuclear receptor

Shinji Hourai1, Luis Cezar Rodrigues, Pierre Antony

  • 1Institut de Génétique et de Biologie Moléculaire et Cellulaire, Département de Biologie et de Génomique Structurales, Université Louis Pasteur, Strasbourg F-67000, France.

Chemistry & Biology
|April 19, 2008
PubMed

Insights

Researchers designed a novel Vitamin D receptor (VDR) superagonist ligand, AMCR277A, by incorporating an oxolane ring. While showing in vitro superagonist activity, it remains as calcemic as the natural ligand in vivo.

Area of Science:

  • Molecular biology
  • Endocrinology
  • Drug discovery

Background:

  • The Vitamin D receptor (VDR) is a key transcriptional regulator targeted for osteoporosis and cancer therapies.
  • VDR ligands can cause hypercalcemia, necessitating the development of superagonists with reduced calcemic effects.
  • Understanding VDR-ligand interactions is crucial for designing safer and more effective therapeutics.

Purpose of the Study:

  • To design and synthesize a novel VDR superagonist ligand with optimized side chain conformation.
  • To evaluate the in vitro and in vivo activity of the designed ligand and its stereoisomers.
  • To elucidate the structural basis for VDR-ligand interactions using crystal structures.

Main Methods:

  • Design of a novel ligand incorporating an oxolane ring to optimize side chain conformation.
  • Synthesis and characterization of two stereoisomers: AMCR277A and AMCR277B.
  • In vitro assays to assess VDR superagonist activity.
  • In vivo studies to evaluate calcemic effects.
  • X-ray crystallography to determine the structures of VDR-ligand complexes.

Main Results:

  • The designed ligand, AMCR277A, demonstrated in vitro VDR superagonist activity.
  • AMCR277A exhibited comparable in vivo calcemic effects to the natural VDR ligand.
  • Crystal structures revealed the binding mode of the novel ligands within the human VDR ligand-binding domain.
  • Stereochemistry significantly influenced the biological activity of the designed compounds.

Conclusions:

  • The novel oxolane-containing ligand, AMCR277A, is a VDR superagonist but retains significant calcemic activity.
  • Structural insights from VDR-ligand complexes provide a foundation for designing improved VDR superagonists.
  • Further optimization is needed to uncouple superagonist activity from calcemic effects for potential clinical applications.

More Related Videos

Methodology for Studying Interactions of Vitamin A Membrane Receptors and Opsin Protein with their Ligands in Generating the Retinylidene Protein08:18

Methodology for Studying Interactions of Vitamin A Membrane Receptors and Opsin Protein with their Ligands in Generating the Retinylidene Protein

Published on: October 4, 2024

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.